High cumulative JC virus seroconversion rate during long-term use of natalizumab

Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

(2015) M. I. Domínguez-Mozo et al.   EUROPEAN JOURNAL OF NEUROLOGY

Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

(2015) Rebekka Kohlmann et al.   Multiple Sclerosis Journal

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

(2015) Anke Vennegoor et al.   Multiple Sclerosis Journal

Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

(2015) Rebekka Kohlmann et al.   Multiple Sclerosis Journal

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

(2015) Anke Vennegoor et al.   Multiple Sclerosis Journal

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

JC Virus in CD34+and CD19+Cells in Patients With Multiple Sclerosis Treated With Natalizumab

(2014) Elliot M. Frohman et al.   JAMA Neurology

The human JC polyomavirus (JCPyV): virological background and clinical implications

(2013) Hans H. Hirsch et al.   APMIS

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

(2013) C. Bozic et al.   EUROPEAN JOURNAL OF NEUROLOGY

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

(2013) Peter Lee et al.   JOURNAL OF CLINICAL VIROLOGY

Changes to anti-JCV antibody levels in a Swedish national MS cohort

(2013) Clemens Warnke et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab

(2013) Olivier Outteryck et al.   Multiple Sclerosis Journal

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

(2013) Tomas Olsson et al.   Multiple Sclerosis Journal

JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis

(2013) Eugene O. Major et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY